依托孕烯植入剂治疗痛经的疗效及安全性分析

发布时间：2019-06-19 20:49

【摘要】：目的:探讨依托孕烯植入剂治疗痛经的疗效及安全性。方法:选择2013年9月至2016年4月在我院埋植依托孕烯植入剂治疗痛经的患者。依托孕烯植入剂植入术后3月、半年、1年进行随访。比较患者术前及术后痛经情况、月经模式、肝肾功能;对子宫腺肌病患者还需比较子宫大小及CA125水平。结果:共73例患者纳入研究,66例术前有中重度痛经,术后3月中、重度痛经者仅10例,占13.7%(χ2=95.312,P=0.000),31例痛经完全消失;3月后痛经情况进一步改善,但与3月比较差异无统计学意义(P0.05)。对于子宫腺肌病患者,术后子宫大小无明显变化(P0.05),术后血清CA125水平显著下降(P0.05)。术后31例(42.5%)患者出现点滴状阴道流血。术后无严重副反应。结论:皮下埋植依托孕烯植入剂是治疗痛经效果确切、较为安全的方法。
[Abstract]:Objective: to investigate the efficacy and safety of etopostene implantation in the treatment of dysmenorrhea. Methods: from September 2013 to April 2016, the patients with dysmenorrhea were treated with progesterone implantation. The patients were followed up for 3 months, 6 months and 1 year after implantation of progesterone implantation. The dysmenorrhea, menstrual pattern and liver and kidney function before and after operation were compared, and the uterine size and CA125 level were also compared in patients with adenomyosis. Results: a total of 73 patients were included in the study, 66 patients had moderate and severe dysmenorrhea before operation, only 10 patients (13.7%) had severe dysmenorrhea 3 months after operation, 31 patients had complete disappearance of dysmenorrhea, and the dysmenorrhea situation was further improved after 3 months, but there was no significant difference compared with 3 months (P < 0.05). For adenomyosis patients, there was no significant change in uterine size (P 0.05), but serum CA125 level decreased significantly (P 0.05). Drip vaginal bleeding occurred in 31 patients (42.5%) after operation. There were no serious side effects after operation. Conclusion: subcutaneous implantation of progesterone implantation is a safe and effective method for the treatment of dysmenorrhea.
【作者单位】：广西医科大学第四附属医院;
【分类号】：R711.51

【相似文献】